Nyrada Quarterly Activities Report & Appendix 4C
- Nyrada remains on track for 2QFY2025 commencement of first in-human Phase I clinical trial for its Brain Injury drug candidate NYR-BI03.
- Good Laboratory Practice (GLP) safety testing studies of NYR-BI03 continuing with results to be progressively disclosed from 1QFY2025.
- Strategic partnership agreement with Rebion to advance research and development of brain injury therapies and outcomes.
- Nyrada Chair and Non-Executive Director CDI subscription completed, raising A$0.21 million (before costs).
- Cash position of A$4.77 million as at 30 June 2024.